Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Late phase II study of NS-304 in intermittent claudication due to arteriosclerosis obliterans
jRCT2031210497Phase 2Completed
- Sponsor
- Nippon Shinyaku
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of selexipag in arteriosclerosis obliterans and intermittent claudication (IC) (2 arms), sponsored by Nippon Shinyaku. Primary endpoint: Natural log transformed peak walking time. Started Feb 2022; status: completed.
02
Drugs
selexipag
03
Conditions
arteriosclerosis obliteransintermittent claudication (IC)
Beyond the preview
Go deeper on jRCT2031210497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210497.